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Abstract 
Primary  neuroendocrine  tumors  of  the
female genital tract have been described in the
cervix, ovaries and uterus.  Large cell neuroen-
docrine carcinoma (LCNC) of the uterine cor-
pus is the least common and appears to behave
the most aggressively. We report a rare case of
a  large  cell  neuroendocrine  tumor  of  the
endometrium. These tumors are not well char-
acterized,  unlike  neuroendocrine  tumors  of
the uterine cervix. Consequently, the optimal
management remains still unclear.  The treat-
ment of our case consisted of surgery, radio-
therapy,  chemotherapy,  and  octreotide.
Despite the aggressive treatment, the patient
died of disease progression 12 months after
the initial diagnosis. We discuss the diagnosis,
prognosis, and treatment options for LCNC of
the genital tract, and potential future thera-
peutics.
Introduction
Neuroendocrine  genital  tract  tumors  are
more  common  in  the  female  than  the  male.
Large  cell  neuroendocrine  carcinoma  of  the
uterine corpus is a rare variant of uterine carci-
noma with features of biologic aggressiveness.
According  to  the  WHO,  large  cell  neuroen-
docrine tumor is synonymous with undifferenti-
ated carcinoma of non-small cell neuroendocrine
typeand defined as a malignant tumor composed
of large cells that show neuroendocrine differen-
tiation. The criterion for neuroendocrine tumor
differentiation relies on a combination of typical
structural,  immunohistochemical  and  ultra-
structural findings.1
Primary  neuroendocrine  tumors  of  the
female genital tract have been described in the
cervix, ovaries and endometrium.  Of these,
large  cell  neuroendocrine  carcinoma  of  the
endometrium is the least common, with only
one previously reported case in the medical lit-
erature. We present the second reported case
of pure large cell neuroendocrine carcinoma of
the endometrium.  
Case Report
A  59-year-old,  gravida  6  para  4,  post-
menopausal Hispanic woman presented with a
six-month history of postmenopausal bleeding.
Her past medical history was significant for
hypertension, diabetes and goiter.  Her mother
had  breast  cancer.  Gynecologic  examination
revealed an enlarged 10 cm uterus with irreg-
ular contour; the cervix and adnexa were nor-
mal.  Poorly differentiated endometrial carci-
noma in sheets and clusters was diagnosed on
endometrial biopsy. The patient’s chest X-ray,
colonoscopy  and  mammogram  were  within
normal limits. CA125 prior to surgery was with-
in normal limit.  Computed Tomography (CT)
of the chest, abdomen and pelvis demonstrated
an enlarged uterus, with a central hypodense
mass measuring 7¥6 cm, pelvic lymph nodes
measuring  up  to  4  cm,  para-aortic  lymph  -
adenopathy measuring up to 3 cm. Exploratory
laparotomy revealed a 12 cm size uterus; the
entire uterine, and bladder serosa, including
peritoneum  was  involved  with  superficial
tumor implants. Ovaries and upper abdomen
were  unremarkable.  Pelvic  and  para-aortic
nodes were enlarged. Surgical staging consist-
ed in washings for cytology, total abdominal
hysterectomy  with  bilateral  salpingo-oopho-
erectomy, bilateral pelvic and para-aortic lym-
phadenectomy,  omentectomy,  appendectomy
and  tumor  debulking  was  performed.
Pathology  examination  demonstrated  a  312
gram uterus. There was a polypoid, tan-white,
fleshy  tumor  covering  the  entire  anterior
endometrium  and  myometrium.  Micro -
scopically, the tumor consisted of a poorly dif-
ferentiated LCNC infiltrating through the full
thickness of myometrium to the uterine serosa
extending to the cervical stroma (Figure 1).
Extensive lymphovascular invasion was pres-
ent. Pelvic and para-aortic lymph nodes were
positive for metastatic carcinoma. On immu -
no  histochemical  evaluation,  the  tumor  cells
were  diffusely  positive  for  synaptophysin
(Figure 2A), Chromogranin A (CgA) (Figure
2B), Neuron Specific Enolase (NSE) (Figure
2C). Additionally, they were patchy positive for
CD56, and focally positive for low molecular
weight cytokeratin (CK 8/18). The tumor was
negative for pan-cytokeratin (AE1/AE3), CD45
(LCA),  TTF-1,  estrogen,  progesterone,  CD10,
p63, p53, s100, c-kit, vimentin, smooth muscle
actin, desmin and HMB-5.  The final pathology
diagnosis was consistent with invasive LCNC. 
Postoperatively, the patient was started on
an  institutional  “sandwiched”  chemoradio-
therapy protocol used in our division for the
post-operative treatment of patients with high
risk  histologic  types  of  endometrial  cancer.
The treatment regimen consists of six cycles of
carboplatin and paclitaxel with radiation ther-
apy administered following the third cycle of
chemotherapy. The CT scan of chest, abdomen
and  pelvis  prior  to  radiation  was  unremark-
able. The radiation therapy consists of stan-
dard whole pelvic therapy with 45 Gy (1.8 Gy
per fraction daily), and vaginal brachytherapy,
15Gy (5Gy per fraction weekly).  After comple-
tion  of  sixth  cycle  of  chemotherapy,  the  CT
scan  demonstrated  soft  tissue  thickening
along the anus and extensive retroperitoneal
lymphadenopathy.  The  patient  then  received
three cycles of pegylated doxorubicin. A follow-
up  CT  revealed  disease  progression,  with
increased  retroperitoneal  lymphadenopathy.
An octreotide scan was performed which was
positive  for  pelvic  lymphadenopathy.  For  the
first time the serum levels of NSE and CgA
were evaluated and measured at 188 units/L
and 72 ng/mL respectively. The patient wished
to continue with aggressive therapy and began
a three cycle combination chemotherapy regi-
men of etoposide (100 mg/m2 IV), cisplatin (75
mg/m2 IV) and long acting depot octreotide 20
mg IM every four weeks. Oral etoposide 200
mg/m2 was also given on days 2-4. Patient did
not  respond  to  three  cycle  of  this  regimen.
During use of this combination chemotherapy
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the NSE level decreased to 55 ng/mL, while the
level of CgA increased to 249 U/L. She died 12
months following her initial diagnosis and sur-
gery from progressive disease. During these 12
months, the patient’s course was complicated
by multiple admissions for DVT, neutropenic
fever, and hyperglycemia.
Discussion
The College of American Pathologists and
the National Cancer Institute workshop recog-
nized  four  general  categories  of  endocrine
tumors.  These  are  typical  (classical),  carci-
noid tumor, large cell neuroendocrine carcino-
ma and small (oat) cell carcinoma. LCNC are
poorly  differentiated  tumors  that  typically
have the neuroendocrine morphologic appear-
ance under light microscopy (organelle nest-
ing,  palisading,  rosettes,  and  trabeculae),
high mitotic rate (>10 mitoses/10 high-power
fields), the presence of necrosis (centrilobular
or in form of a large area), the presence of
large  cell  size,  low  nuclear  to  cytoplasmic
ratio,  vesicular  chromatin,  and  prominent
nuclei,  and  positive  immunohistochemical
staining  for  one  or  more  neuroendocrine
markers NSE, CgA and synaptophysin.2 Among
these general tumor markers CgA, although
its precise function has not been established,
has been shown to be a very sensitive and spe-
cific serum marker for various types of neu-
roendocrine tumors.  It is elevated in 50-100%
of patients with neuroendocrine tumors. CgA
serum  or  plasma  levels  may  reflect  tumor
load.3 LCNCs of the lung and the cervix are
characterized  by  early  tumor  recurrence
despite  radical  surgery,  radiotherapy  and
chemotherapy.  These  tumors  are  highly
aggressive  neoplasms.  In  clinico-pathologic
study of 16 cases of LCNC of the cervix, the
progression of disease was within 2 years of
diagnosis.4, 5 LCNC of the endometrium is a
rare, aggressive tumor with an assumed unfa-
vorable outcome similar to LCNC of the cervix.
In  the  one  reported  case  of  LCNC  of  the
endometrium, the patient developed cerebral
and pulmonary metastases after surgery and
adjuvant radiotherapy and died 4 months after
recurrence.6 Our case is the second report of a
LCNC of the endometrium and the first case
who had the trial of octreotide treatment. Our
patient reported increasing serum values of
CgA, which was consistent with progressive
disease and non-response to treatment.
Adjuvant  chemotherapy  (cisplatin,  carbo-
platin, etoposide or cyclophosphamide based,
5-fluorouracil,  streptozocin,  paciltaxel)  has
been used in the management of LCNC of the
lung and cervix4,5 Since the biological activity
and reason for aggressive behavior for neu-
roendocrine tumors is not well delineated at
present,  targeted  therapy  is  limited  to
octreotide. Octreotide is a synthetic octapep-
tide with a structure and activity similar to
somatostatin.7 Somatostatin  receptors  are
essential for transmitting the response from
somatostatin or its analogs, and they are high-
ly represented in neuroendocrine tumors. The
role  of  somatostatin  analogs  in  inhibiting
tumor  growth  has  been  demonstrated  in  a
number of animal models and human tumor
cell lines. The potential mechanisms include
inhibition  of  the  secretion  of  hormones
involved  in  the  regulation  of  tumor  growth,
direct or indirect inhibition of IGF-1, and/or
other growth factors with a stimulatory effect
on tumor growth, inhibition of angiogenesis,
and a direct inhibitory effect on the tumor via
specific somatostatin receptors.7
In  the  single  case  report  of  the  use  of
octreotide for small cell neuroendocrine tumor
of the endometrium, a partial response was
reported.8 In our case the patient had progres-
sion  of  the  disease  with  combination  of
chemotherapy  and  octreotide  treatment
regardless  of  having  an  octreotide  positive
scan. Octreotide in general, is well tolerated.
However,  we  observed  a  well-known  side
effect of octreotide, namely poor glycemic con-
trol especially in patients with diabetes. The
patient  described  here  reported  repeated
episodes of hypo- and hyperglycemia.
Due to the rarity of these tumors the opti-
mal  therapy  has  not  yet  been  delineated.
Although a treatment recommendation cannot
be established from our report, a review of the
literature on LCNC of the lung and cervix sug-
gests that primary multimodality therapy may
improve prognosis in these patients.
Case Report
Figure  1.  A)  Immunohistochemical  analysis  of  large  cell  neuroendocrine  carcinoma
showing a composition of sheets and organoid large cells with abundant eosinophilic
cytoplasm and small eosinophilic cytoplasmic granules. B) Larger magnification of large
cell neuroendocrine carcinoma tissue showing cells with vesicular high grade nuclei with
prominent nucleoli and many mitoses.
Figure 2. Immunohistochemical staining showing expression of specific neuroendocrine markers: Synaptophysin (A), Chromagranin
(B) and Neuron Specific Enolase (C).[Rare Tumors 2011; 3:e41] [page 131]
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